Search bioRxiv⌕ Search

Biology subjects

Winn, A.

Publications and source records attributed to Winn, A..

2 recordsLinked to original sources

The latent stage of Toxoplasma gondii is targeted by the immune response and host protective

Latency is a microbial strategy for persistence. For Toxoplasma gondii the ability of the bradyzoite stage to form long-lived cysts is critical for transmission, while their presence in neurons is considered important for immune evasion. Development of a mathematical model highlighted that immune pressure on bradyzoites should contribute to dynamics of cyst formation and reactivation. Experimental data demonstrated that a cyst-derived antigen was recognized by CD8+ T cells and that IFN-{gamma} signaling in neurons contributes to cyst control. In addition, modeling and the use of a parasite strain unable to form bradyzoites revealed that this stage was not required for long-term persistence, but the absence of cyst formation resulted in increased tachyzoite replication in the CNS with associated tissue damage and mortality. Thus, the latent form of T. gondii is under immune pressure, mitigates infection-induced damage, and promotes survival of host and parasite.

microbiology↗

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.1.7 and B.1.351 VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 g) or low (0.2 g) immunogen dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose two vaccinations. SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

immunology↗